May 24, 2012 — Avaxia Biologics Inc., a privately held biotechnology company developing oral antibody drugs that act locally within the gastrointestinal tract, announced this week that the company was awarded U.S. Patent 8,182,818, entitled "Methods of Using Anti-TNF Antibodies for Treating Radiation Damage to the Digestive Tract."
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now